Citations

Showing 10 of 108135 citations.

Clinical Consensus Statement: Balloon Dilation of the Eustachian Tube
Tucci, Debara L. , Tunkel, David E. , Batra, Pete S., Chandrasekhar, Sujana S. , Cordes, Susan R., Kaylie, David M. , Lee, Jivianne, Setzen, Michael, Sindwani, Raj , Syms, Charles A., Bishop, Charles E. , Poe, Dennis S. , Corrigan, Maureen D. , Lambie, Erin M., McCoul, Edward D. , Rosenfeld, Richard M. , Eshraghi, Adrien A. , Lal, Devyani , Lee, Jivianne T.

Mayo Clinic

Otolaryngology–Head and Neck Surgery | June 4, 2019 | Volume: 161 | Issue: 1 | Pages: 6-17

10.1177/0194599819848423 | PMID 31161864 Get It

ObjectiveTo develop a clinical consensus statement on the use of balloon dilation of the eustachian tube (BDET).MethodsAn expert panel of otolaryngologists was assembled with nominated representatives of general otolaryngology and relevant subspecialty societies. The target population was adults 18 years or older who are candidates for BDET because of obstructive eustachian tube dysfunction (OETD) in 1 or both ears for 3 months or longer that significantly affects quality of life or functional health status. A modified Delphi method was used to distill expert opinion into clinical statements that met a standardized definition of consensus.ResultsAfter 3 iterative Delphi method surveys, 28 statements met the predefined criteria for consensus, while 28 statements did not. The clinical statements were grouped into 3 categories for the purposes of presentation and discussion: (1) patient criteria, (2) perioperative considerations, and (3) outcomes.ConclusionThis panel reached consensus on several statements that clarify diagnosis and perioperative management of OETD. Lack of consensus on other statements likely reflects knowledge gaps regarding the role of BDET in managing OETD. Expert panel consensus may provide helpful information for the otolaryngologist considering the use of BDET for the management of patients with OETD.
Neuroimaging correlates with neuropathologic schemes in neurodegenerative disease
Lowe, Val J. , Lundt, Emily S. , Albertson, Sabrina M., Przybelski, Scott A. , Senjem, Matthew L. , Parisi, Joseph E., Kantarci, Kejal , Jack, Clifford R. , Petersen, Ronald C. , Murray, Melissa E. , Jack, Clifford R , Senjem, Matthew L , Kantarci, Kejal , Murray, Melissa E , Boeve, Bradley F. , Jones, David T. , Knopman, David S. , Dickson, Dennis W. , Lundt, Emily S

Mayo Clinic

Alzheimer's & Dementia | June 4, 2019 | Volume: 15 | Issue: 7 | Pages: 927-939

10.1016/j.jalz.2019.03.016 | PMID 31175025 Get It

Abstract Introduction Neuroimaging biomarkers are important for early diagnosis of Alzheimer's disease, and comparing multimodality neuroimaging to autopsy data is essential. Methods We compared the pathologic findings from a prospective autopsy cohort (n = 100) to Pittsburgh compound B PET (PiB‐PET), 18 F‐fluorodeoxyglucose PET (FDG‐PET), and MRI. Correlations between neuroimaging biomarkers and neuropathologic schemes were assessed. Results PiB‐PET showed strong correlations with Thal amyloid phase and Consortium to Establish a Registry for Alzheimer's Disease score and categorized 44% of Thal phase 1 participants as positive. FDG‐PET and MRI correlated modestly with Braak tangle stage in Alzheimer's type pathology. A subset of participants with “none” or “sparse” neuritic plaque scores had elevated PiB‐PET signal due to diffuse amyloid plaque. Participants with findings characterized as “suspected non‐Alzheimer's pathophysiology” represented 15% of the group. Discussion PiB‐PET is associated with Alzheimer's disease, neuritic plaques, and diffuse plaques. FDG‐PET and MRI have modest correlation with neuropathologic schemes. Participants with findings characterized as suspected non‐Alzheimer's pathophysiology most commonly had primary age‐related tauopathy.
Efficacy of Pharmacologic and Cardiac Implantable Electronic Device Therapies in Patients With Heart Failure and Reduced Ejection Fraction
Lee, Justin Z. , Amin, Mustapha, Neville, Matthew R., Almader‐Douglas, Diana , Killu, Ammar M. , Madhavan, Malini , Cha, Yong‐Mei , Asirvatham, Samuel J. , Friedman, Paul A. , Mulpuru, Siva K. , Tseng, Andrew S. , Kunze, Katie L. , Almader-Douglas, Diana, Asirvatham, Samuel J , Gersh, Bernard J.

Mayo Clinic

Circulation: Arrhythmia and Electrophysiology | June 4, 2019 | Volume: 12 | Issue: 6 | Pages: No page available

10.1161/circep.118.006951 | PMID 31159582 Get It

Background: The treatment of heart failure with reduced ejection fraction has been the subject of numerous randomized controlled trials involving medications and cardiac implantable electronic device therapies. As newer effective pharmacological therapies suggest significant reductions in all-cause mortality, the role of additional device therapy in heart failure with reduced ejection fraction deserves further scrutiny. Methods: A systematic review and network meta-analysis on the effect of medication and device therapies in heart failure with reduced ejection fraction on all-cause mortality was performed. Randomized controlled trials published between January 1980 and July 2017 were identified using Medline, EMBASE, and Cochrane Controlled Register of Trials databases. Pcnetmeta package in R was used to calculate treatment arm–based estimated rates, rate ratios, and probability ranks with 95% credible intervals. Results: Combination therapy of ACE (angiotensin-converting enzyme) inhibitors or ARBs (angiotensin receptor blockers) with β-blockers (BBs) alone or in addition to implantable cardiac defibrillators or cardiac resynchronization therapy with defibrillators demonstrated a significant reduction of all-cause mortality when compared with placebo. By probability rank, implantable cardiac defibrillator+ACE inhibitor or ARB+BB+mineralocorticoid receptor antagonist, implantable cardiac defibrillator+ACE inhibitor or ARB+BB, and angiotensin receptor-neprilysin inhibitor+BB+mineralocorticoid receptor antagonist combination therapies have the highest probability of being ranked the best treatment. There was no significant difference in the rate of mortality when comparing angiotensin receptor-neprilysin inhibitor+BB+mineralocorticoid receptor antagonist to implantable cardiac defibrillator+optimal pharmacological combination therapy. Conclusions: BB and renin-angiotensin system blockers alone or in combination with defibrillator device therapy have robust evidence for a reduction in mortality compared with placebo. The comparative efficacy of pharmacological therapy with angiotensin receptor-neprilysin inhibitors and device therapy deserves further investigation.
Disease Activity, Antineutrophil Cytoplasmic Antibody Type, and Lipid Levels in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis
Wallace, Zachary S. , Liao, Katherine P. , Kallenberg, Cees G. M., Langford, Carol A. , Clair, E. William St. , Zhang, Yuqing , Stone, John H. , Liao, Katherine , Choi, Hyon , Fu, Xiaoqing , Merkel, Peter A. , Monach, Paul A. , Seo, Philip , Specks, Ulrich , Spiera, Robert , Choi, Hyon K.

Mayo Clinic

Arthritis & Rheumatology | June 4, 2019 | Volume: 71 | Issue: 11 | Pages: 1879-1887

10.1002/art.41006 | PMID 31162829 Get It

ObjectivePatients with antineutrophil cytoplasmic antibody (ANCA)–associated vasculitis (AAV) have an elevated risk of cardiovascular disease (CVD). This study was undertaken to develop a clearer understanding of the association between changes in disease activity and lipid levels in AAV, which may inform CVD risk stratification in this population.MethodsLipid levels were assessed in stored serum samples (obtained at baseline and month 6) from the Rituximab for ANCA‐Associated Vasculitis (RAVE) trial, which randomized patients to receive either rituximab or cyclophosphamide followed by azathioprine. Paired t‐tests and multivariable linear regression were used to assess changes in lipid levels.ResultsOf the 142 patients with serum samples available, the mean ± SD age was 52.3 ± 14.7 years, 72 (51%) were male, 95 (67%) were proteinase 3 (PR3)–ANCA positive, 72 (51%) had received a new diagnosis of AAV, and 75 (53%) were treated with rituximab. Several lipid levels increased between baseline and month 6, including total cholesterol (+12.4 mg/dl [95% confidence interval (95% CI) +7.1, +21.0]), low‐density lipoprotein (+10.3 mg/dl [95% CI +6.1, +17.1]), and apolipoprotein B (+3.5 mg/dl [95% CI +1.0, +8.3]). These changes were observed among newly diagnosed and PR3‐ANCA–positive patients but not among those with relapsing disease or myeloperoxidase‐ANCA–positive patients. There was no difference in change in lipid levels between rituximab‐treated patients and cyclophosphamide‐treated patients. Changes in lipid levels correlated with changes in erythrocyte sedimentation rate but not with other inflammatory markers or glucocorticoid exposure.ConclusionLipid levels increased during remission induction among patients with newly diagnosed AAV and those who were PR3‐ANCA positive. Disease activity and ANCA type should be considered when assessing lipid profiles to stratify CVD risk in patients with AAV.
Test collections for electronic health record-based clinical information retrieval
Wang, Yanshan , Hersh, William , Liu, Sijia , Hersh, William , Wen, Andrew , Bedrick, Steven , Liu, Hongfang , Wang, Yanshan

Mayo Clinic

JAMIA Open | June 4, 2019 | Volume: 2 | Issue: 3 | Pages: 360-368

10.1093/jamiaopen/ooz016 | PMID 31709390 Get It

AbstractObjectivesTo create test collections for evaluating clinical information retrieval (IR) systems and advancing clinical IR research.Materials and MethodsElectronic health record (EHR) data, including structured and free-text data, from 45 000 patients who are a part of the Mayo Clinic Biobank cohort was retrieved from the clinical data warehouse. The clinical IR system indexed a total of 42 million free-text EHR documents. The search queries consisted of 56 topics developed through a collaboration between Mayo Clinic and Oregon Health & Science University. We described the creation of test collections, including a to-be-evaluated document pool using five retrieval models, and human assessment guidelines. We analyzed the relevance judgment results in terms of human agreement and time spent, and results of three levels of relevance, and reported performance of five retrieval models.ResultsThe two judges had a moderate overall agreement with a Kappa value of 0.49, spent a consistent amount of time judging the relevance, and were able to identify easy and difficult topics. The conventional retrieval model performed best on most topics while a concept-based retrieval model had better performance on the topics requiring conceptual level retrieval.DiscussionIR can provide an alternate approach to leveraging clinical narratives for patient information discovery as it is less dependent on semantics. Our study showed the feasibility of test collections along with a few challenges.ConclusionThe conventional test collections for evaluating the IR system show potential for successfully evaluating clinical IR systems with a few challenges to be investigated.
Non-vitamin K antagonist oral anticoagulants in adults with a Fontan circulation: are they safe
Yang, Hayang , Veldtman, Gruschen , Bouma, Berto J. , Budts, Werner , Niwa, Koichiro , Meijboom, Folkert J., Egbe, Alexander C. , Schwerzmann, Markus , Broberg, Craig S. , Buber, Jonathan , Tsai, Shane, Post, Martijn C. , Mulder, Barbara J.M. , Egbe, Alexander Chima, Schwerzmann, Markus , Scognamiglio, Giancarlo , Morissens, Marielle , Polyzois, Ioannis , Greutmann, Matthias , Dijk, Arie P.J. van , Aboulhosn, Jamil , Bouma, Berto J

Mayo Clinic

Open Heart | June 4, 2019 | Volume: 6 | Issue: 1 | Pages: e000985

10.1136/openhrt-2018-000985 | PMID 31245011 Get It

Background In Fontan patients with atrial arrhythmias (AA), non-vitamin K antagonist oral anticoagulants(NOACs) have a class III recommendation according to the Pediatric & Congenital Electrophysiology Society (PACES)/Heart Rhythm Society (HRS) guideline in 2014, due to lack of data on outcomes as opposed to evidence of harm. To address this gap in data, we investigated the safety and efficacy of NOACs in adults with a Fontan circulation in a worldwide study. Methods This is an international multicentre prospective cohort study, using data from the NOTE ( n on-vitamin K antagonist o ral anticoagulants for t hrombo e mbolic prevention in patients with congenital heart disease) registry. The study population comprised consecutive adults with a Fontan circulation using NOACs. Follow-up took place at 6 months and yearly thereafter. The primary endpoints were thromboembolism and major bleeding. Secondary endpoint was minor bleeding. Results From April 2014 onward, 74 patients (mean age 32±10 years (range 18–68), 54% male) with a Fontan circulation using NOACs were included. During a median follow-up of 1.2 (IQR 0.8–2.0) years, three thromboembolic events (2.9 per 100 patient-years (95% CI 0.7 to 7.6)) and three major bleedings (2.9 per 100 patient-years (95% CI 0.7 to 7.6)) occurred in five atriopulmonary Fontan and one total cavopulmonary connection Fontan patients with AA. Fifteen patients experienced minor bleeding episodes (15.8 per 100 patient-years (95% CI 9.1 to 25.2)). In patients (n=37) using vitamin K antagonists (VKAs) prior to the initiation of NOAC, annual incidence of historical thromboembolic events and major bleeding were 2.4% (95% CI 0.4% to 7.4%) (n = 2) and 1.2% (95% CI 0.7% to 5.1%) (n = 1), respectively. Conclusions In this review of the largest Fontan cohort using NOACs with prospective follow-up, NOACs appear to be well tolerated and their efficacy and safety during short-term follow-up seem comparable to VKAs. Longer term data are required to confirm these promising short-term results.
Timing of Postoperative Radiotherapy in Surgically Treated HPV‐Positive Oropharyngeal Squamous Cell Carcinoma
Townsend, Melanie, DeWees, T.A. , Gross, Jennifer H. , Daly, Mackenzie, Jackson, Ryan S. , DeWees, Todd, DeWees, Todd A , Gay, Hiram A. , Thorstad, Wade

Mayo Clinic

Otolaryngology–Head and Neck Surgery | June 4, 2019 | Volume: 161 | Issue: 2 | Pages: 297-306

10.1177/0194599819847144 | PMID 31159646 Get It

ObjectiveOptimal timing of postoperative radiotherapy (PORT) remains understudied in human papillomavirus (HPV)–related oropharyngeal squamous cell carcinoma. Objectives are to determine if delays between surgery and radiotherapy, breaks during radiotherapy, disease, or patient factors are associated with recurrence or survival decrements in HPV‐related disease.DesignRetrospective review.SettingAcademic medical center.SubjectsA total of 240 cases of HPV‐positive oropharyngeal squamous cell carcinoma from 2000 to 2016.MethodsPatient and tumor characteristics (American Joint Committee on Cancer, eighth edition), delays to radiation initiation, and breaks during radiation were recorded. Overall survival (OS) and recurrence‐free survival (RFS) were analyzed.ResultsRFS and OS were not significantly affected by delays to PORT >6 weeks or by treatment intervals >100 days (surgery to PORT completion). Breaks during PORT significantly imparted an OS detriment (hazard ratio [HR], 2.4; 95% CI, 1.2‐4.8). Advanced‐stage disease was significantly associated with reduced RFS and OS. Subgroup analysis of stage I versus stage II/III disease found that >6 weeks to PORT initiation and treatment intervals >100 days did not significantly decrease RFS or OS in either stage group. Advanced‐stage disease was significantly associated with worsened OS (HR, 6.6; 95% CI, 2.3‐19.1) and RFS (HR, 5.3; 95% CI, 1.5‐18.4). Breaks during PORT significantly reduced RFS (HR, 3.6; 95% CI, 1.2‐10.8) and OS (HR, 3.2; 95% CI, 1.2‐9.0) in the stage II/III subset.ConclusionDelays to radiotherapy initiation and prolonged treatment time did not affect recurrence or survival in HPV‐related oropharyngeal disease. Locoregionally advanced disease was consistently associated with worse outcomes. Breaks during PORT may affect recurrence and survival, although larger studies are needed to confirm this finding.
Accurate Precursor Mass Assignment Improves Peptide Identification in Data-Independent Acquisition Mass Spectrometry
Nam, Dowoon , Kim, Hokeun , Pandey, Akhilesh , Lee, Sang‐Won , Pandey, Akhilesh , Lee, Sang-Won , Mun, Dong‐Gi

Mayo Clinic

Analytical Chemistry | June 3, 2019 | Volume: 91 | Issue: 13 | Pages: 8453-8460

10.1021/acs.analchem.9b01474 | PMID 31247731 Get It

Epidemiology of Injuries in Ice Hockey
Anderson, Gregory R., Melugin, Heath P. , Stuart, Michael J.

Mayo Clinic

Sports Health: A Multidisciplinary Approach | June 3, 2019 | Volume: 11 | Issue: 6 | Pages: 514-519

10.1177/1941738119849105 | PMID 31158326 Get It

Context: Hockey is a skillful contact sport with an elevated injury risk at higher levels of play. An understanding of injury incidence, type, mechanism, and severity at various levels of competition aids the clinician treating these athletes. The purpose of this clinical review is to discuss the epidemiology of hockey injuries at various levels of participation, including youth, high school, junior, college, and professional. Evidence Acquisition: A literature search was performed by a review of PubMed, Embase, and Cochrane databases and included articles published from 1988 to 2017. Studies were included in this review if determined to be of high quality and containing injury data relevant to the levels of competition. Pertinent data regarding ice hockey injury epidemiology and prevention at various levels of competition were analyzed. Study Design: Clinical review. Level of Evidence: Level 4. Results: Youth, high school, junior, college, and professional hockey players have unique injury patterns. Injuries occur much more often in a game compared with a practice, and injury risk increases with each level of competition. Preventative measures, such as mandatory facial protection and delayed body checking in games until age 13 years, are proven strategies to reduce the risk of facial injury and concussion. Conclusion: An understanding of common injury types and mechanisms according to age and level of play aids the clinician in diagnosis and management. This information can also guide preventative strategies in the areas of education, coaching, rule enforcement, rule modifications, equipment improvement, and sportsmanship.
Clinical and Histopathologic Features of Immune Checkpoint Inhibitor-related Pneumonitis
Larsen, Brandon T. , Chae, June, Dixit, Anuj , Hartman, Thomas E. , Peikert, Tobias, Roden, Anja C.

Mayo Clinic

American Journal of Surgical Pathology | June 3, 2019 | Volume: 43 | Issue: 10 | Pages: 1331-1340

10.1097/pas.0000000000001298 | PMID 31162288 Get It

Immune checkpoint inhibitors (ICIs) have revolutionized oncology, but are associated with immune-related adverse events. Clinically, pneumonitis is a well-recognized complication, but its histopathologic features are poorly understood. Institutional archives were searched for patients having ICI therapy and subsequent lung tissue sampling. After excluding infectious cases, 9 patients (5 women, median: 59 y) were identified with clinically suspected ICI-related pneumonitis. Clinical history, imaging, and pathology slides were reviewed. Patients received pembrolizumab (6 cases), nivolumab (1), ipilimumab followed by pembrolizumab (1), or pembrolizumab followed by nivolumab (1); the latter experienced pneumonitis with both agents. Treatment duration ranged from 1 to 33 cycles (median: 8). Three patients received concurrent chemotherapy and 1 received radiation; the remainder received ICI monotherapy. Symptoms were nonspecific; 2 patients were asymptomatic. Thoracic imaging showed bilateral ground glass or nodular opacities in all cases, often with pleural effusion. Histologically, organizing pneumonia was seen in 7 patients, all with subclinical or mild disease, admixed with vague non-necrotizing airspace granulomas in 3 cases; all 6 patients with follow-up did well. One patient had acute fibrinous pneumonitis and 1 had diffuse alveolar damage; both died. All 9 cases showed foamy macrophages and pneumocyte vacuolization; 6 had rare eosinophils. ICI-related pneumonitis presents as bilateral ground-glass opacities or nodules, and usually manifests as organizing pneumonia histopathologically, often with vague non-necrotizing airspace granulomas. Foamy macrophages and pneumocyte vacuolization are characteristic and rare eosinophils are often seen. Less commonly, acute fibrinous pneumonitis or diffuse alveolar damage can occur, which may be fatal.